AUTHOR=Chen Catherine Z. , Shinn Paul , Itkin Zina , Eastman Richard T. , Bostwick Robert , Rasmussen Lynn , Huang Ruili , Shen Min , Hu Xin , Wilson Kelli M. , Brooks Brianna M. , Guo Hui , Zhao Tongan , Klump-Thomas Carleen , Simeonov Anton , Michael Samuel G. , Lo Donald C. , Hall Matthew D. , Zheng Wei TITLE=Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 JOURNAL=Frontiers in Pharmacology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.592737 DOI=10.3389/fphar.2020.592737 ISSN=1663-9812 ABSTRACT=

Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drugs and 49 investigational drugs. The anti-SARS-CoV-2 activities of 230 of these confirmed compounds, of which 38 are approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA-approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set is a useful resource for drug repurposing efforts, including design of new drug combinations for clinical trials for SARS-CoV-2.